UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus. The drug, tecovirimat, is approved by the U.S. Food and Drug Administration to treat smallpox. Investigators hope this study will establish whether the drug is also safe and effective for treating monkeypox.
“There is an urgent need for monkeypox treatments, and this study will help us get critical information about the safety and effectiveness of tecovirimat at treating this infection,” said Dr. Rachel Bender Ignacio, a physician-scientist and assistant professor of allergy and infectious diseases at the University of Washington School of Medicine. “People living in the Seattle area who have monkeypox have the opportunity to make a huge contribution by participating in this study.”
